PHARMACEUTICALS

Articles and editorials

Accutane Blamed in Suicide, H138 [1FE]

Help Is Here Express Visits Sulphur, E529 [6AP]

High Cost of Drug Caps, S7425 [12JY]

New Program Will Help Uninsured Get Cheaper Prescriptions, E537 [6AP]

Bills and resolutions

Agriculture: prohibit open-air cultivation or use of human food or animal feed as host plant and establish tracking system to regulate genetically engineered pharmaceutical and industrial crops (see H.R. 5267), H1979 [2MY]

Business and industry: prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 3582), S6560 [27JN]

———require prescription drug manufacturers, packers, and distributors to disclose certain gifts provided in connection with promotional or marketing activities (see H.R. 4718), H223 [8FE]

Dept. of HHS: establish a Biodefense Injury Compensation Program (see S. 2291), S1353 [15FE]

———require the incorporation of counterfeit-resistant technologies into the packaging of prescription drugs (see S. 2668), S3703 [27AP] (see H.R. 4829), H508 [1MR]

Diseases: increase assistance to countries for the prevention, treatment, and control of tuberculosis (see S. 2465), S2467 [28MR] (see H.R. 5022), H1195 [28MR]

———promote research and development of drugs related to neglected and tropical diseases (see S. 2699), S3893 [2MY]

Drug abuse: reduce deaths occurring from overdoses of drugs or controlled substances (see S. 3557), S6419 [22JN]

Drugs: impose requirements on Internet pharmacies, require manufacturers to implement chain-of-custody procedures, and restrict exemption on importation of controlled substances for personal use (see H.R. 4769), H387 [16FE]

———promote safe and ethical clinical trials of drugs and other test articles on people overseas (see H.R. 5641), H4327 [20JN]

———remove market exclusivity for certain drugs in order to enhance competition, improve access to generic drugs, and reduce consumer prices (see S. 2300), S1413 [16FE]

Education: enhance research and education in the areas of pharmaceutical and biotechnology science and engineering (see S. 2793), S4469 [11MY]

Federal Food, Drug, and Cosmetic Act: amend relative to distribution of the drug dextromethorphan (see H.R. 5280), H2101 [3MY]

———increase penalties relative to counterfeit drugs (see H.R. 5156), H1678 [6AP]

Health: permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (see S. 2618), S3378 [7AP]

Health care providers: establish a volunteer corps to aid in dissemination and distribution of vaccines and other countermeasures during a public health emergency (see S. 3482), S5659 [8JN]

International AIDS Vaccine Initiative (nonprofit organization): anniversary (see H. Res. 844), H3308 (see H. Res. 844), H3361 [25MY]

Medicare: deliver a meaningful benefit and lower prescription drug prices (see S. 2342), S1579 [1MR]

———eliminate months from calculation of any late enrollment penalty under the prescription drug program and provide additional funding for State health insurance counseling programs and area agencies on aging (see S. 2810), S4617 [16MY]

———eliminate prescription drug late enrollment penalty (see H.R. 5399), H2704 (see H.R. 5399), H2757 [17MY]

———encourage eligible beneficiaries who have not enrolled in the prescription drug benefit to review available options and determine whether enrolling best meets their prescription drug needs (see H. Res. 802), H2338 [9MY]

———ensure adequate payment amounts for drugs and biologicals (see H.R. 5179), H1741 [25AP]

———extend annual, coordinated election period under the prescription drug program and provide for a refund of excess premiums paid (see S. 2811), S4617 [16MY]

———extend annual coordinated election period for prescription drug plans (see H.R. 4715), H223 [8FE]

———extend eligibility period for ``Welcome to Medicare'' physical examination and eliminate coinsurance for screening mammography and colorectal cancer screening tests (see H.R. 5437), H2961 [19MY]

———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, allow prescription drug plan enrollment changes during the first year of enrollment, and limit drug formulary changes (see H.R. 5263), H1979 [2MY]

———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, allow prescription drug plan enrollment changes once a year, and limit drug formulary changes (see H.R. 5116), H1677 [6AP]

———extend open enrollment period for prescription drug plans and eliminate penalties for late enrollment in such plans (see H.R. 4938), H867 [9MR]

———extend open enrollment period for prescription drug plans and Medicare Advantage-Prescription Drug plans (see H.R. 4723), H224 [8FE]

———extend open enrollment period for prescription drug plans and Medicare Advantage-Prescription Drug plans without any late enrollment penalty (see H.R. 5387), H2640 [16MY]

———improve access to pharmacies under part D (see S. 2664), S3703 [27AP]

———improve implementation of prescription drug program (see H.R. 4796), H388 [16FE]

———improve payments made by prescription drug plans and Medicare Advantage-Prescription Drug plans to pharmacies for covered drugs (see H.R. 5166), H1679 [6AP]

———include costs incurred by certain agencies, health centers, or drug assistance programs toward the out-of-pocket treshold of the prescription drug program (see S. 3650), S7415 [12JY]

———limit the penalty for late enrollment in the prescription drug program (see H.R. 5750), H4957 [10JY]

———permit beneficiaries enrolled in Medicare or Medicare Advantage prescription drug plans that change their formularies or increase prices to enroll in other plans (see S. 2313), S1414 [16FE]

———prohibit removal of covered drugs from prescription drug plan formularies during the plan year (see S. 2255), S864 [8FE] (see H.R. 5102), H1562 [5AP]

———provide a special enrollment period for enrollment under the prescription drug program (see H.R. 5596), H3907 [13JN]

———provide a special enrollment period for enrollment under the prescription drug program and waive the late enrollment penalty for low-income individuals who enroll during such period (see H.R. 5691), H4679 [27JN]

———provide for a Medicare Prescription Drug Ombudsman (see H.R. 5433), H2961 [19MY]

———provide for counting expenses for nonformulary drugs against the annual out-of-pocket threshold for costs for covered drugs (see H.R. 4928), H867 [9MR]

———provide for same treatment of all individuals who applied for low-income subsidies for enrollment and waiver of late enrollment penalties under the Medicare part D program (see H.R. 5629), H4134 [15JN]

———provide residents of long-term facilities with assistance relative to prescription drug coverage (see S. 2184), S123 [25JA]

———reform the prescription drug program (see S. 2240), S510 [2FE] (see H.R. 4792), H388 [16FE]

———replace the prescription drug benefit with a revised and simplified program for all beneficiaries (see H.R. 4697), H154 [1FE]

———require prescription drug plans to provide enrollee notice of less expensive part D covered drugs that may be substituted for dispensed drugs (see H.R. 4743), H273 [14FE]

———require prompt payment to pharmacies, restrict pharmacy co-branding on prescription drug cards, and provide guidelines for Medication Therapy Management Services programs under prescription drug program (see S. 2563), S3211 [6AP]

———require the sponsor of a prescription drug plan or an organization offering a Medicare Advantage-Prescription Drug plan to promptly pay submitted claims (see S. 2723), S4050 [4MY] (see H.R. 5182), H1741 [25AP] (see H.R. 5307), H2174 [4MY]

———simplify and improve the prescription drug program (see S. 2665), S3703 [27AP]

———suspend prescription drug late enrollment penalty (see H.R. 5173), H1741 [25AP] (see H.R. 5336), H2501 [10MY]

———waive monthly beneficiary premium under prescription drug plan or Medicare Advantage-Prescription Drug plan during months in which an enrollee has a gap in coverage (see S. 3647), S7415 [12JY]

Medicare/Medicaid: assure uninterupted access to necessary medicines under the prescription drug benefit (see S. 2238), S446 [1FE] (see H.R. 4685), H153 [1FE]

———dual eligible benefits continuity, off-label uses of certain prescription drugs and biological products, and determinations denying coverage and certain costs incurred by pharmacies (see H.R. 5193), H1741 [25AP]

———eliminate cost-sharing for certain dual eligible populations under the prescription drug benefit (see S. 2234), S446 [1FE] (see H.R. 4722), H224 [8FE]

———eliminate cost-sharing for dual eligible populations under the prescription drug benefit (see S. 2203), S211 [26JA]

———provide for continuity of coverage of prescription drugs under the prescription drug plans for full-benefit dual eligible individuals (see H.R. 4937), H867 [9MR]

———provide for necessary dual eligible beneficiary protections in order to ensure access to the prescription drug benefit program (see S. 2183), S19 [20JA] (see S. 2183), S123 [25JA] (see H.R. 4660), H23 [31JA]

———reduce cost-sharing for certain dual eligible populations under the prescription drug benefit (see S. 2409), S2122 [14MR]

———reimburse States for costs incurred by covering dual eligible populations under the Medicare prescription drug benefit plan (see S. 2181), S19 [20JA] (see S. 2181), S123 [25JA] (see H.R. 4663, 4665), H23 (see H.R. 4675), H24 [31JA] (see H.R. 4721), H223 [8FE]

National security: prepare and strengthen biodefenses against deliberate, accidental, and natural outbreaks of illness (see S. 2564), S3211 [6AP] (see H.R. 5533), H3423 [6JN]

Patents: establish procedures for granting compulsory patent licenses for exporting patented pharmaceutical products to certain countries consistent with international commitments made by the U.S. (see S. 3175), S5229 [25MY]

Prices: provide for prices that are fair to the producer and the consumer (see H.R. 4850), H564 [2MR]

Tariff: aerosol valves designed to deliver a metered dose (50 microliters) of a pressurized liquid pharmaceutical (see S. 2505), S2799 [4AP]

Taxation: add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund (see H.R. 5135), H1677 [6AP]

———add papillomavirus vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund (see H.R. 5495), H3307 (see H.R. 5495), H3359 [25MY]

———deny deduction for certain gifts and benefits provided to physicians by prescription drug manufacturers (see H.R. 4706), H160 [7FE]

———expand human clinical trials qualifying for the orphan drug credit (see H.R. 5080), H1452 [4AP]

———modernize treatment of biomedical research corporations (see H.R. 5115), H1676 [6AP]

Excerpts

Dept. of HHS indemnification clause in contract with Chiron Corp., S3778 [1MY]

Dept. of HHS special product liability and indemnification clause in contract with Sanofi Pasteur Inc., S3778 [1MY]

Letters

Deny tax deduction for certain gifts and benefits provided to physicians by prescription drug manufacturers: Leana S. Wen and Christopher P. McCoy, American Medical Student Association Foundation, E77 [7FE]

Investigation of the role of Alexander Strategy Group in the development of Deficit Reduction Act provisions dealing with pharmaceutical companies: Representative Waxman, Committee on Government Reform (House), H41 [1FE]

Lower Prices Reduced With Increased Competition and Efficient Development of Drugs (Lower PRICED Drugs) Act: Annette Guarisco, Coalition for a Competitive Pharmaceutical Market, S1422 [16FE]

———David P. Sloane, AARP, S1422 [16FE]

———Kathleen Jaeger, Generic Pharmaceutical Association, S1422 [16FE]

———Ken W. Cole, General Motors Corp., S1422 [16FE]

Permit negotiation of fair prices for prescription drugs and use resulting savings for budget deficit reduction: David P. Sloane, AARP, S2020 [13MR]

Request for a compulsory license for cancer drug Avastin: Respresentative Kucinich, E535 [6AP]

Veterans health care funding: Dennis Cullinan, VFW, S2094 [14MR]

———several veterans organizations, S2081 [14MR]

Remarks in House

Africa Malaria Day: observance, E650 [27AP]

Agriculture: prohibit open-air cultivation or use of human food or animal feed as host plant and establish tracking system to regulate genetically engineered pharmaceutical and industrial crops (H.R. 5267), E687 [2MY]

Armed Forces: limit increase in the cost of TRICARE health care services, H2361, H2365 [10MY], H2511, H2513, H2517, H2545 [11MY]

Asthma Awareness Day: observance, H1986 [3MY]

Budget: allocation of funds, H650 [8MR]

Bureau of Customs and Border Patrol: confiscation and destruction of reimported prescription drugs from Canada, H299 [15FE], H3289 [25MY]

Centers for Medicare & Medicaid Services: provide for product specific reimbursement for separate immune globulins and recognize infusion of immune globulins as a biologic response modifier, E52 [1FE]

Congress: relationship with special interest groups, H301 [15FE]

Democratic Party: national agenda, H4181-H4187 [16JN]

Dept. of HHS: AIDS Drug Assistance Program funding, H3365 [6JN]

Diseases: combat avian flu, increase local preparedness, and create a program to develop a vaccine, H4537-H4540 [26JN], H5042-H5044 [11JY]

———improve access to HIV/AIDS-related treatments and services in developing countries, H4203 [19JN]

———improve preparation for an influenza pandemic, including an avian influenza pandemic, H1984, H1988 [3MY], H3708 [9JN], E812 [12MY]

———provide assistance to countries to combat tuberculosis, H3690 [9JN]

Drugs: establish certain restrictions on drugs containing isotretinoin, including the drug marketed as Accutane, H138 [1FE]

Families USA (organization): study on Medicare prescription drug plans, E1254 [23JN], E1310 [28JN]

FDA: Center for Veterinary Medicine animal antibiotic use study funding, H3093 [23MY]

———improve ability to ensure drug safety, H3077 [23MY]

———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (H.R. 1079), H1136 [28MR]

Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, H3526 [8JN]

Health: improve patient safety and reduce incidence of medical errors, H793 [9MR]

———link between child vaccinations containing mercury and autism, H357 [16FE]

———repeal comprehensive liability protection for manufacturers of avian flu pandemic vaccines and products, H1092, H1093 [16MR]

Knoxville, TN: anniversary of Long's Drug Store, E393 [16MR]

Medicare: deliver a meaningful benefit and lower prescription drug prices (H.R. 752), E825 [12MY], E1254 [23JN], E1310 [28JN]

———encourage eligible beneficiaries who have not enrolled in the prescription drug benefit to review available options and determine whether enrolling best meets their prescription drug needs (H. Res. 802), H2472-H2480 [10MY], E801 [11MY], E825 [12MY], E916 [19MY]

———ensure Medicare providers give accurate and complete information to senior citizens regarding prescription drug coverage, H5095 [12JY]

———extend annual coordinated election period for prescription drug plans and eliminate prescription drug late enrollment penalty, H4965 [11JY]

———extend implementation of prescription drug program, H978, H979 [15MR], H1064, H1065, H1066, H1090-H1092 [16MR], H1133 [28MR], H1203, H1310, H1312 [29MR], H1628 [6AP], H1748 [26AP], H1873 [27AP], H1925 [2MY], H2186, H2187 [9MY], H2345, H2473-H2480 [10MY], H2507, H2559, H2581 [11MY], H2647, H2648 [17MY], E649 [27AP]

———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, allow prescription drug plan enrollment changes during the first year, and limit drug formulary changes (H.R. 5263), H2763 [18MY], E825 [12MY]

———extend initial enrollment period for prescription drug benefits and waive penalties for late enrollment (H.R. 4399), H1713 [25AP]

———implementation of prescription drug program, H3800 [13JN], H4373 [21JN]

———negotiate for lower prices for prescription drugs, eliminate gap in coverage of prescription drug benefits, and promulgate regulations for the reimportation of prescription drugs, H147, H148 [1FE]

———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs, H4333 [21JN]

———permit negotiation of fair prices for prescription drugs, H4967 [11JY]

———prescription drug benefit coverage, H473 [1MR], H600 [7MR], H794, H795, H848 [9MR], H979 [15MR], H1134, H1135, H1136 [28MR], H1202, H1301-H1307, H1314 [29MR], H1326, H1369 [30MR], H1400, H1401 [4AP], H1455, H1459 [5AP], H1664-H1670 [6AP], H1683, H1684, H1685 [25AP], H1830-H1836 [26AP], H1884 [27AP], H1926 [2MY], H2341, H2344, H2345, H2495-H2499 [10MY], H2644, H2646, H2647 [17MY], H3231 [25MY], H4223 [20JN], H4686, H4687 [28JN], H5032, H5033 [11JY], E303 [8MR]

———prohibit negotiation of prices for prescription drugs, H1883 [27AP]

———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (H.R. 3861), H1987 [3MY]

———reform the prescription drug program, H162 [8FE], H277, H278, H279, H300 [15FE], H436 [28FE], H468, H484 [1MR], H551 [2MR], H1164 [28MR], H1367 [30MR], H1425, H1428 [4AP], H1593 [6AP], H2644 [17MY]

———require the sponsor of a prescription drug plan or an organization offering a Medicare Advantage-Prescription Drug plan to promptly pay submitted claims (H.R. 5182), H1953 [2MY]

Medicare/Medicaid: assure uninterupted access to necessary medicines under the prescription drug benefit (H.R. 4685), E55, E57 [1FE]

Onondaga County, NY: tribute to Onondaga County Dept. of Aging participation in Medicare Part D enrollment, E1103 [9JN]

Patient Assistance Day: observance, E529, E536 [6AP]

Pharmacies: impact of Medicare prescription drug benefit implementation and of Medicaid pharmacy reimbursement cuts, H240 [14FE], H356 [16FE]

Republican Party: national agenda, H1200 [29MR]

Social Security: privatization proposals, H4201 [19JN]

Taxation: deny deduction for certain gifts and benefits provided to physicians by prescription drug manufacturers (H.R. 4706), E76 [7FE]

Remarks in Senate

Armed Forces: prohibit increase in copayments for TRICARE prescription drug program, S5740 [13JN], S5837-S5840 [14JN]

Business and industry: prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 3582), S6577-S6579 [27JN]

Canada: permit commercial importation of prescription drugs from Canada, S1514 [28FE]

Dept. of HHS: establish a Biodefense Injury Compensation Program (S. 2291), S1360 [15FE]

Dept. of Homeland Security: prevent Bureau of Customs and Border Protection seizure of imported prescription drugs for personal use, S7295-S7302, S7304, S7305 [11JY]

Diseases: combat avian flu, increase local preparedness, and create a program to develop a vaccine, S2226, S2227, S2231 [16MR]

———improve and secure an adequate supply of influenza vaccine (S. 1828), S5629-S5631 [8JN]

———improve preparation for an influenza pandemic, including an avian influenza pandemic, S969 [9FE]

———increase assistance to countries for the prevention, treatment, and control of tuberculosis (S. 2465), S2472 [28MR]

———pandemic influenza vaccine injury compensation funding, S3778, S3779 [1MY], S3942, S3948 [3MY]

———promote research and development of drugs related to neglected and tropical diseases (S. 2699), S3900 [2MY]

———provide assistance to countries to combat avian influenza, S1887 [8MR]

Drug abuse: reduce deaths occurring from overdoses of drugs or controlled substances (S. 3557), S6422 [22JN]

Drugs: delay implementation of voluntary prescription drug benefit program, extend Medicare prescription drug discount card and transitional assistance programs, and Medicaid coverage of prescription drugs, S404 [1FE]

———remove market exclusivity for certain drugs in order to enhance competition, improve access to generic drugs, and reduce consumer prices (S. 2300), S1420 [16FE]

Education: enhance research and education in the areas of pharmaceutical and biotechnology science and engineering (S. 2793), S4476 [11MY]

FDA: condemn delay of decision on the approval of over-the-counter emergency contraceptives, S7181 [29JN]

Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, S2268, S2269 [16MR]

Government regulations: importation of prescription drugs, S4194 [9MY]

———importation of prescription drugs (S. 334), S7301 [11JY]

Health: permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (S. 2618), S3390 [7AP]

———provide liability protection to manufacturers of pandemic vaccines, S3778, S3779 [1MY]

Medicaid: funding, S723 [6FE]

Medicare: eliminate months from calculation of any late enrollment penalty under the prescription drug program and provide additional funding for State health insurance counseling programs and area agencies on aging (S. 2810), S4645 [16MY], S4725 [17MY]

———extend annual, coordinated election period under the prescription drug program and provide for a refund of excess premiums paid (S. 2811), unanimous-consent request, S4579, S4580 [16MY]

———extend implementation of prescription drug program, S2148-S2154, S2177, S2178 [15MR], S4176 [9MY], S4247-S4250, S4256, S4298, S4382 [10MY], S4427-S4430, S4434, S4447, S4451, S4454, S4455 [11MY], S4543 [15MY]

———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, allow prescription drug plan enrollment changes during the first year, and limit drug formulary changes, S4568-S4570 [15MY]

———extend initial enrollment period for prescription drug benefits and provide other additional beneficiary protections, S422 [1FE]

———extend open enrollment period for prescription drug plans and eliminate penalties for late enrollment in such plans, S4325 [10MY]

———improve access to pharmacies under part D (S. 2664), S3710 [27AP]

———improve implementation of the prescription drug benefit, S482-S484, S490, S491 [2FE], S1086 [13FE]

———include costs incurred by certain agencies, health centers, or drug assistance programs toward the out-of-pocket treshold of the prescription drug program (S. 3650), S7424 [12JY]

———permit beneficiaries enrolled in Medicare or Medicare Advantage prescription drug plans that change their formularies or increase prices to enroll in other plans (S. 2313), S1526-S1528 [28FE]

———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs, S4101 [5MY], S6470 [26JN]

———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs (S. 239), S358 [31JA]

———permit negotiation of fair prices for prescription drugs, S4174, S4175 [9MY], S4298 [10MY]

———permit negotiation of fair prices for prescription drugs and use resulting savings for budget deficit reduction, S2020 [13MR], S2165-S2168, S2178, S2179 [15MR]

———prescription drug benefit coverage, S111 [25JA], S358 [31JA], S857-S859 [8FE], S1055 [10FE], S1493 [27FE], S1514 [28FE], S4190 [9MY]

———prohibit removal of covered drugs from prescription drug plan formularies during the plan year (S. 2255), S865, S866 [8FE]

———provide a prescription drug benefit program which is administered directly through Medicare, S2266 [16MR]

———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (S. 1841), S4123 [8MY], S4324 [10MY], S4543 [15MY]

———reform the prescription drug program, S1340-S1342 [15FE]

———reform the prescription drug program (S. 2240), S512 [2FE]

———require prompt payment to pharmacies, restrict pharmacy co-branding on prescription drug cards, and provide guidelines for Medication Therapy Management Services programs under prescription drug program (S. 2563), S3220-S3222 [6AP]

———require the sponsor of a prescription drug plan or an organization offering a Medicare Advantage-Prescription Drug plan to promptly pay submitted claims (S. 2723), S4454 [11MY]

———simplify and improve the prescription drug program (S. 2665), S3710 [27AP]

———State health insurance assistance programs funding, S4456 [11MY]

———waive monthly beneficiary premium under prescription drug plan or Medicare Advantage-Prescription Drug plan during months in which an enrollee has a gap in coverage (S. 3647), S7421 [12JY]

Medicare/Medicaid: eliminate cost-sharing for dual eligible populations under the prescription drug benefit (S. 2203), S230 [26JA]

———funding, S1083-S1086 [13FE], S1137 [14FE]

———provide for necessary dual eligible beneficiary protections in order to ensure access to the prescription drug benefit program, S482-S485, S491 [2FE]

———reduce cost-sharing for certain dual eligible populations under the prescription drug benefit (S. 2409), S2124, S2125 [14MR]

———reimburse States for costs incurred by covering dual eligible populations under the Medicare prescription drug benefit plan (S. 2181), S23-S25 [20JA], S130, S131 [25JA]

Patents: establish procedures for granting compulsory patent licenses for exporting patented pharmaceutical products to certain countries consistent with international commitments made by the U.S. (S. 3175), S5245-S5247 [25MY]

Senate: legislative priorities, S5626 [8JN]

Veterans: expand and enhance health care, mental health, transition, and disability benefits, S6594 [28JN]

———expand and enhance health care, mental health, transition, and disability benefits (S. 13), S6526 [27JN]

———health care funding, S2075-S2083, S2094, S2095 [14MR]

Reports

Lobbying Disclosure Act Requirements: Alexander Strategy Group, H41-H44 [1FE]

Statements

Partnership for Prescription Assistance Launches National ``Patient Assistance Day'' Celebration on April 5, 2006: Partnership for Prescription Assistance (organization), E536 [6AP]

Summaries

Genetically Engineered Pharmaceutical and Industrial Crop Safety Act (H.R. 5267), E688 [2MY]

Testimonies

Medicare Prescription Drug Benefit Coverage: Tobey Schule, S858 [8FE]

Texts of

H. Res. 802, encourage eligible beneficiaries who have not enrolled in the Medicare prescription drug benefit to review available options and determine whether enrolling best meets their prescription drug needs, H2472 [10MY]

S. 2181, Medicare State Reimbursement Act, S24 [20JA], S130 [25JA]

S. 2183, Requiring Emergency Pharmaceutical Access for Individual Relief (REPAIR) Act, S25-S27 [20JA], S132-S134 [25JA]

S. 2240, Medicare Part D Reform Act, S512 [2FE]

S. 2291, Responsible Public Readiness and Emergency Preparedness Act, S1361-S1363 [15FE]

S. 2300, Lower Prices Reduced With Increased Competition and Efficient Development of Drugs (Lower PRICED Drugs) Act, S1421 [16FE]

S. 2313, Medicare Drug Honest Pricing Act, S1432 [16FE]

S. 2563, Pharmacist Access and Recognition in Medicare (PhARM) Act, S3220 [6AP]

S. 2564, Biodefense and Pandemic Vaccine and Drug Development Act, S3222-S3227 [6AP]

S. 2810, Medicare Late Enrollment Assistance Act, S4621 [16MY]

S. 3175, Life-Saving Medicines Export Act, S5247-S5252 [25MY]

S. 3557, Drug Overdose Reduction Act, S6422 [22JN]

S. 3582, Preserve Access to Affordable Generics Act, S6578 [27JN]

S. 3647, Prescription for Fairness Act, S7422 [12JY]

S. 3650, Helping Fill the Medicare Rx Gap Act, S7425 [12JY]